Shows & Panels
- AFCEA Answers
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Connected Government
- Constituent Servicing
- Continuous Monitoring: Tools and Techniques for Trustworthy Government IT
- The Cyber Imperative
- Cyber Solutions for 2013 and Beyond
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Mission-critical Apps in the Cloud
- The Modern Federal Threat Landscape
- The Path from Legacy Systems
- The Real Deal on Digital Government
- The Reality of Continuous Monitoring... Is Your Agency Secure?
- Veterans in Private Sector: Making the Transition
Shows & Panels
News Summary: Ranbaxy recalls generic Lipitor
Friday - 11/23/2012, 1:25pm EST
(AP) - DRUG DANGER: Indian drugmaker Ranbaxy is recalling dozens of lots of its generic version of cholesterol blockbuster Lipitor. Some bottles may contain tiny bits of glass.
KEEPING MUM: Ranbaxy isn't giving any other details while it investigates.
DEJA VU: It's the latest in a series of problems, dating to 2006, involving manufacturing deficiencies at multiple Ranbaxy factories and alleged doctoring of test results on some medicines. U.S. regulators had banned imports of 30 Ranbaxy medicines and wouldn't approve any new products for sale until Ranbaxy agreed to make improvements and be monitored by a third party for five years.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)